Ipertrofan

Mepartricin, the active ingredient in Ipertrofan, is a macrolide antibiotic presented as an oral tablet for prescription use. It is employed to treat bacterial infections, particularly in the urinary and genitourinary tracts, and is indicated for conditions such as urinary tract infections and prostatitis. GNH USA supplies Ipertrofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipertrofan (mepartricin) is used to manage bacterial infections affecting the urinary and genitourinary systems. - Urinary tract infection: eradicates susceptible bacteria and alleviates symptoms. - Chronic prostatitis: reduces bacterial load and associated inflammation. - Bacterial vaginosis: helps restore normal vaginal flora by targeting pathogenic organisms.

Adverse reactions may occur with any antibiotic therapy.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: increased bowel movements, sometimes watery. - Abdominal pain: cramping or discomfort. - Headache: transient mild headache. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, swelling of face or throat. - Hepatotoxicity: elevated liver enzymes or jaundice. - Clostridioides difficile colitis: severe diarrhea with abdominal pain. - Hematologic abnormalities: neutropenia or thrombocytopenia. - Cardiac arrhythmia: QT prolongation in susceptible patients.

Before prescribing Ipertrofan, clinicians should consider patient history and potential risks. - Allergy assessment: avoid if known hypersensitivity to macrolides. - Liver function: monitor in patients with hepatic impairment. - Renal function: adjust if severe renal insufficiency is present. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Mepartricin may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Cyclosporine: increased serum levels may cause nephrotoxicity. - Statins (e.g., simvastatin): risk of myopathy and rhabdomyysis. - Warfarin: potentiation of anticoagulant effect, leading to bleeding.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption of mepartricin. - Digoxin: possible increase in serum concentration. - Oral contraceptives: reduced efficacy, consider alternative contraception.